impact of tenofovir disoproxil fumarate on kidney function: four-year data from the HIV-infected outpatient cohort. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. renal failure after initiation of tenofovir disoproxil fumarate. et al. Tenofovir-related nephrotoxicity in human immunodefi-ciency virus-infected patients: three cases of ...

ABACAVIR+LAMIVUDINE+ZIDOVUDINE (TRIZIVIR, TZV) ABACAVIR+DOLUTEGRAVIR+LAMIVUDINE (TRIUMEQ, TRI) ADEFOVIR DIPIVOXIL (HEPSERA, ADV) AMPRENAVIR (AGENERASE, APV) (AGENERASE NO LONGER MANUFACTURED AS OF 2007) ATAZANAVIR (REYATAZ, ATV) ATAZANAVIR+COBICISTAT (EVOTAZ, EVO) COBICISTAT (TYBOST, COBI) DARUNAVIR (PREZISTA, DRV) DARUNAVIR+COBICISTAT (PREZCOBIXTM, REZOLSTATM, PCX) DELAVIRDINE MESYLATE (RESCRI...

This study investigated the effects of ingested food types on the pharmacokinetics of elvitegravir, cobicistat, emtricitabine, and tenofovir as a single-tablet regimen (STR) in Japanese HIV-negative healthy subjects. In this open-label, randomized, three-way crossover study, the pharmacokinetic profiles of elvitegravir, cobicistat, emtricitabine, and tenofovir were evaluated when administered w...

INTRODUCTION Tenofovir disoproxil fumarate (Viread((R))) is the only nucleotide reverse transcriptase inhibitor currently approved for the treatment of HIV. It is frequently prescribed not only for its efficacy but also for its decreased side effect profile compared with other nucleotide analogs. In addition, it is now increasingly recognized as a cause of acquired Fanconi's syndrome in individ...

BACKGROUND BMS-986001 is a thymidine analogue nucleoside reverse transcriptase inhibitor (NRTI) designed to maintain in-vitro antiviral activity while minimising off-target effects. We assessed the efficacy and safety of BMS-986001 versus tenofovir disoproxil fumarate in treatment-naive patients with HIV-1. METHODS In this phase 2b, randomised, active-controlled trial (AI467003), we recruited...

www.thelancet.com Vol 385 June 27, 2015 2559 Since the late 1980s, progressive development of antiretroviral drugs has revolutionised care for people with HIV infection. Early generation antiretrovirals saved the lives of patients dying from AIDS, in exchange for a high pill burden and substantial morbidity. However, such treatment was susceptible to treatment failure, especially before the int...

Tenofovir disoproxil fumarate (tenofovir DF) is a bioavailable prodrug of tenofovir, a potent nucleotide analogue reverse-transcriptase inhibitor with activity against human immunodeficiency virus (HIV) and hepatitis B virus. It is administered as a single 300-mg tablet once daily. It was approved for the treatment of HIV infection on the basis of data from clinical trials demonstrating activit...

A stability-indicating high-performance thin-layer chromatographic (HPTLC) method for determination of tenofovir disoproxil fumarate in bulk drug and in tablet has been developed and validated. The mobile phase selected was chloroform:methanol (9.0:1.0, v/v) with ultraviolet (UV) detection at 260 nm. The retention factor was found to be 0.49 ± 0.03 with correlation coefficients of 0.9994 in the...

Studies of tenofovir disoproxil fumarate (TDF)-emtricitabine (FTC)-based preexposure prophylaxis (PrEP) have not focused on transgendered women who are at disproportionate risk of HIV acquisition. Concerns exist for drug interactions between cross-sex therapy (estradiol, progestins, and spironolactone) with tenofovir disoproxil fumarate-emtricitabine. This review assessed the experimental and t...

Three UV spectrophotometric methods have been developed, simultaneous equation method, multicomponent analysis (II) and derivative spectroscopy method (III). The absorption maxima of the drugs were found to be 247, 259 and 272 nm, respectively for efavirenz, tenofovir disoproxil fumarate and lamivudine in methanol:water (50:50) solvent system. Efavirenz, tenofovir disoproxil fumarate and lamivu...